The Cancer Letter

Inside information on cancer research and drug development

Letter To The Editor

A reminder: The real goal is saving lives

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Dear Editor,

I was disappointed to see that you reported on the results of the IMpassion 131 trial, without context. [The Cancer Letter, Sept. 4, 2020]

I often see stories touting increased funding at NCI and changes in the payline. However, these are not the ultimate goals we are all working toward. More money, more research, and more researchers are simply the tools to achieve the real goal: saving lives. Is the system set up to accomplish the real goal? I continue to question that.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Frances M. Visco, JD
President, National Breast Cancer Coalition
Table of Contents

YOU MAY BE INTERESTED IN

Cancer History ProjectGuest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
By Katerina A. Politi and Roy S. Herbst
Byline
Frances M. Visco, JD
President, National Breast Cancer Coalition
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account